HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $8.47 million. The enterprise value is $17.47 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 1.12 million shares outstanding. The number of shares has increased by 7.97% in one year.
| Current Share Class | 1.12M |
| Shares Outstanding | 1.12M |
| Shares Change (YoY) | +7.97% |
| Shares Change (QoQ) | +11.84% |
| Owned by Insiders (%) | 40.21% |
| Owned by Institutions (%) | 6.71% |
| Float | 503,714 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.84 |
| Forward PS | n/a |
| PB Ratio | -1.25 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19
| Current Ratio | 0.19 |
| Quick Ratio | 0.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -46.71 |
Financial Efficiency
Return on equity (ROE) is -897.37% and return on invested capital (ROIC) is -137.31%.
| Return on Equity (ROE) | -897.37% |
| Return on Assets (ROA) | -62.72% |
| Return on Invested Capital (ROIC) | -137.31% |
| Return on Capital Employed (ROCE) | -4,851.08% |
| Revenue Per Employee | $71,300 |
| Profits Per Employee | -$833,995 |
| Employee Count | 36 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.53% in the last 52 weeks. The beta is 0.82, so HCW Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -86.53% |
| 50-Day Moving Average | 11.68 |
| 200-Day Moving Average | 17.77 |
| Relative Strength Index (RSI) | 34.31 |
| Average Volume (20 Days) | 15,053 |
Short Selling Information
The latest short interest is 8,895, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 8,895 |
| Short Previous Month | 390,944 |
| Short % of Shares Out | 0.79% |
| Short % of Float | 1.77% |
| Short Ratio (days to cover) | 1.59 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $2.57 million and -$30.02 million in losses. Loss per share was -$30.96.
| Revenue | 2.57M |
| Gross Profit | 959,403 |
| Operating Income | -29.48M |
| Pretax Income | -27.39M |
| Net Income | -30.02M |
| EBITDA | -28.30M |
| EBIT | -29.48M |
| Loss Per Share | -$30.96 |
Full Income StatementBalance Sheet
The company has $4.67 million in cash and $13.69 million in debt, giving a net cash position of -$9.02 million or -$8.03 per share.
| Cash & Cash Equivalents | 4.67M |
| Total Debt | 13.69M |
| Net Cash | -9.02M |
| Net Cash Per Share | -$8.03 |
| Equity (Book Value) | -6.77M |
| Book Value Per Share | -6.08 |
| Working Capital | -23.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.23 million and capital expenditures -$261,617, giving a free cash flow of -$14.49 million.
| Operating Cash Flow | -14.23M |
| Capital Expenditures | -261,617 |
| Free Cash Flow | -14.49M |
| FCF Per Share | -$12.90 |
Full Cash Flow StatementMargins
| Gross Margin | 37.38% |
| Operating Margin | -1,148.50% |
| Pretax Margin | -1,169.70% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |